Article

How Do Socioeconomic Factors Impact Cancer Patient Survival?

More than just biological factors can affect patient outcomes.

More than just biological factors can affect patient outcomes.

Young patients who are single, have poor insurance, and who have lower incomes are at an increased chance of dying from acute myelogenous leukemia (AML), a recent study indicates.

The research, published in Cancer, suggest that efforts are needed to address the social factors that impact critical aspects of health in these patients. AML is a deadly disease that will affect approximately 21,000 people and kill 10,000 people in 2015 in the United States alone.

Tremendous strides have been made in identifying risk factors for patients who have underwent intensive treatment. Now, investigators at the University of Alabama at Birmingham (UAB) are looking into non-biological patient characteristics to see how they affect patient outcomes.

The study found that patients who were single or divorced, patients who were uninsured or were Medicaid beneficiaries, and patients who lived in areas with lower income had substantially elevated risks of dying prematurely.

“We believe these three factors indicate lack of material and social support preventing young patients from successfully walking the long and difficult road towards a cure,” said lead author Uma Borate, MD, assistant professor in the UAB Division of Hematology and Oncology.

The findings clearly indicate that more than just biological factors contribute to patient outcomes in AML treatment.

“As physicians, we often emphasize more of the biology of the cancer, especially with the recent focus on personalized medicine,” said senior author Luciano Jose Costa, MD, PhD, associate professor in the UAB Division of Hematology and Oncology. “But we need to pay the same attention to resources available to our patients, as this greatly impacts their chances to survive leukemia.”

This will be especially important as the United States transitions to a health care system that ties physician and hospital payments to patient outcomes.

“Taking from the results of this study, factors that have nothing to do with quality of care need to be accounting for when comparing predicted with actual outcomes—otherwise we will create a disincentive for hospitals and doctors to care for less privileged patients,” Dr. Borate said.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards